| Symbol | BCRX |
|---|---|
| Name | BIOCRYST PHARMACEUTICALS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 4505 EMPEROR BOULEVARD, DURHAM, NC 27703 |
| Telephone | 919-859-1302 |
| Fax | — |
| — | |
| Website | https://www.biocryst.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000882796 |
| Description | BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocrysts research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology. Additional info from NASDAQ: |
2026-06-29 11:06
(10% Negative) BIOCRYST PHARMACEUTICALS INC (BCRX) Announces Delay in enrollment Trials for Birmingham Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Efficacy Assessment
Read more
2026-06-29 11:00
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
Read more
2026-06-15 20:32
Director Milne Jill C. 🟢 acquired 48.8K shares (1 derivative) of BIOCRYST PHARMACEUTICALS INC (BCRX) at $8.50 Transaction Date: Jun 11, 2026 | Filing ID: 000055
Read more
2026-06-15 20:30
Director Galson Steven K 🟢 acquired 48.8K shares (1 derivative) of BIOCRYST PHARMACEUTICALS INC (BCRX) at $8.50 Transaction Date: Jun 11, 2026 | Filing ID: 000053
Read more
2026-06-15 20:29
Director LEVIN ALAN G 🟢 acquired 48.8K shares (1 derivative) of BIOCRYST PHARMACEUTICALS INC (BCRX) at $8.50 Transaction Date: Jun 11, 2026 | Filing ID: 000052
Read more
2026-06-15 20:16
Director Frank Steven 🟢 acquired 48.8K shares (1 derivative) of BIOCRYST PHARMACEUTICALS INC (BCRX) at $8.50 Transaction Date: Jun 11, 2026 | Filing ID: 000045
Read more
2026-06-15 20:14
Director SANDERS MACHELLE 🟢 acquired 48.8K shares (1 derivative) of BIOCRYST PHARMACEUTICALS INC (BCRX) at $8.50 Transaction Date: Jun 11, 2026 | Filing ID: 000043
Read more
2026-06-15 20:12
Director MILANO VINCENT 🟢 acquired 48.8K shares (1 derivative) of BIOCRYST PHARMACEUTICALS INC (BCRX) at $8.50 Transaction Date: Jun 11, 2026 | Filing ID: 000041
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04428632 | Oral Berotralstat Expanded Access Program | — | Hereditary Angioedema | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT00486980 | Intramuscular Peramivir for the Treatment of Uncomplicated Influenza | Phase3 | Influenza | Withdrawn | — | — | ClinicalTrials.gov |
| NCT00002237 | A Study of Peldesine (BCX-34) in HIV-Infected Patients | Phase1 | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT07228559 | A Study of Avoralstat In Participants With Diabetic Macular Edema | Phase1 | Diabetic Macular Edema (DME) | Terminated | 2025-10-02 | 2026-04-17 | ClinicalTrials.gov |
| NCT06539507 | A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BC… | Phase1 | Netherton Syndrome | Recruiting | 2024-09-26 | 2026-12-01 | ClinicalTrials.gov |
| NCT06100900 | Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobi… | Phase1 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2023-10-24 | 2024-12-11 | ClinicalTrials.gov |
| NCT05741346 | Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobi… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria | Terminated | 2023-01-18 | 2025-01-31 | ClinicalTrials.gov |
| NCT05453968 | Berotralstat Treatment in Children With Hereditary Angioedema | Phase3 | Hereditary Angioedema | Active_Not_Recruiting | 2022-10-25 | 2027-02-01 | ClinicalTrials.gov |
| NCT05162066 | Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Eith… | Phase2 | Complement 3 Glomerulopathy | Terminated | 2022-02-18 | 2022-09-23 | ClinicalTrials.gov |
| NCT05116774 | BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Parti… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Terminated | 2021-12-06 | 2023-09-14 | ClinicalTrials.gov |
| NCT05116787 | BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Parti… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Terminated | 2021-10-26 | 2023-09-18 | ClinicalTrials.gov |
| NCT04933721 | Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotrals… | Phase3 | Hereditary Angioedema | Enrolling_By_Invitation | 2021-07-23 | 2031-08-01 | ClinicalTrials.gov |
| NCT04702568 | A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal H… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria | Terminated | 2020-12-18 | 2023-10-04 | ClinicalTrials.gov |
| NCT03891420 | A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galid… | Phase1 | COVID-19 | Terminated | 2020-04-09 | 2021-04-30 | ClinicalTrials.gov |
| NCT04330534 | First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH | Phase1 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2020-03-03 | 2021-01-25 | ClinicalTrials.gov |
| NCT03873116 | Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for t… | Phase3 | Hereditary Angioedema, HAE | Completed | 2018-12-27 | 2021-07-08 | ClinicalTrials.gov |
| NCT03800173 | A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics o… | Phase1 | Marburg Virus Disease | Completed | 2018-12-10 | 2019-04-30 | ClinicalTrials.gov |
| NCT03472040 | A Long Term Safety Study of BCX7353 in Hereditary Angioedema | Phase2 | Hereditary Angioedema | Completed | 2018-02-16 | 2022-04-27 | ClinicalTrials.gov |
| NCT03485911 | Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of… | Phase3 | Hereditary Angioedema | Completed | 2018-02-06 | 2022-04-06 | ClinicalTrials.gov |
| NCT03240133 | Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema | Phase2 | Hereditary Angioedema (HAE) | Completed | 2017-07-31 | 2019-01-29 | ClinicalTrials.gov |
| NCT03202784 | A Relative Bioavailability Study of Two Formulations of BCX7353 | Phase1 | Hereditary Angioedema | Completed | 2017-02-27 | 2017-09-30 | ClinicalTrials.gov |
| NCT03136237 | A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions | Phase1 | Hereditary Angioedema | Completed | 2017-02-17 | 2017-08-15 | ClinicalTrials.gov |
| NCT02870972 | Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With H… | Phase2 | Hereditary Angioedema (HAE) | Completed | 2016-08-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT02819102 | An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on … | Phase1 | Hereditary Angioedema | Completed | 2016-03-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02635724 | Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subject… | Phase3 | Influenza | Completed | 2015-12-01 | 2018-09-01 | ClinicalTrials.gov |
| NCT02670720 | Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary An… | Phase3 | Hereditary Angioedema | Terminated | 2015-12-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02448264 | First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and… | Phase1 | Hereditary Angioedema | Completed | 2015-05-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02369159 | Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Su… | Phase3 | Influenza | Completed | 2015-03-11 | 2020-05-14 | ClinicalTrials.gov |
| NCT02303626 | 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE… | Phase2 | Hereditary Angioedema | Completed | 2014-12-17 | 2016-01-01 | ClinicalTrials.gov |
| NCT02319772 | A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BC… | Phase1 | Filovirus Infections | Completed | 2014-12-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02218294 | Study to Determine How BCX4161 is Metabolized and Eliminated by the Body | Phase1 | Hereditary Angioedema | Completed | 2014-08-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT02125162 | A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the… | Phase1 | Hereditary Angioedema | Completed | 2014-04-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01984788 | Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE | Phase2 | Hereditary Angioedema | Completed | 2013-11-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01407874 | A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Eff… | Phase2 | Gout | Completed | 2011-09-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT02665351 | Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lo… | Phase2 | Influenza | Completed | 2011-02-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01265264 | Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine … | Phase2 | Gout | Completed | 2010-12-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01224795 | A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subject… | Phase3 | Influenza | Withdrawn | 2010-10-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01129648 | Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX420… | Phase2 | Gout | Completed | 2010-05-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00958776 | A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Stan… | Phase3 | Cough | Terminated | 2009-11-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00957996 | Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspect… | Phase3 | Seasonal Influenza | Completed | 2009-10-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00985127 | Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Admini… | Phase2 | Gout | Completed | 2009-09-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00705406 | A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The… | Phase2 | Acute, Uncomplicated Human Influenza | Completed | 2008-07-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00640523 | Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL) | Phase2 | Chronic Lymphocytic Leukemia (CLL) | Completed | 2008-03-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00610935 | Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza | Phase3 | Influenza | Terminated | 2008-01-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00453999 | Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or … | Phase2 | Influenza | Completed | 2007-07-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00501735 | Forodesine in the Treatment of Cutaneous T-Cell Lymphoma | Phase2 | Cutaneous T-cell Lymphoma (CTCL), | Completed | 2007-07-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00419263 | Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicat… | Phase2 | Influenza | Completed | 2007-01-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00419081 | Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precurso… | Phase2 | Leukemia | Terminated | 2006-07-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00289549 | Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refrac… | Phase2 | Leukemia, Lymphocytic, Chronic | Completed | 2005-06-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00098332 | Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB… | Phase1 | Lymphoma | Completed | 2004-11-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00289562 | Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia | Phase1 | B-cell Acute Lymphoblastic Leukemia | Completed | 2004-09-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00095381 | Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Ad… | Phase2 | Leukemia, T-Cell | Completed | 2004-03-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00073944 | BCX-1777 in Treating Patients With Refractory Cancer | Phase1 | Cancer | Completed | 2003-04-01 | — | ClinicalTrials.gov |
| NCT00061880 | BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma | Phase1 | Lymphoma | Completed | 2003-02-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00035022 | Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leuke… | Phase1 | Leukemia, Lymphocytic | Completed | 2001-08-01 | 2004-03-01 | ClinicalTrials.gov |
Total clinical trials: 55
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| BCX17725 | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| Placebo Comparator | Other | Phase PHASE3 | Influenza | WITHDRAWN | NCT01224795 |
| Peramivir | Other | Phase PHASE3 | Influenza | WITHDRAWN | NCT01224795 |
| Placebo | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| BCX17725 | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| Peramivir 300mg | Other | Phase PHASE3 | Influenza | WITHDRAWN | NCT00486980 |
| Peramivir 150mg | Other | Phase PHASE3 | Influenza | WITHDRAWN | NCT00486980 |
| Placebo | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| BCX17725 | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| Placebo | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| BCX17725 | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| Placebo | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| BCX17725 | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| Placebo | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| BCX17725 | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| Placebo | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| BCX17725 | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| Placebo | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| BCX17725 | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| Placebo | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| BCX17725 | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| Placebo | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| BCX17725 | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| Placebo | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| BCX17725 | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| Placebo | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| BCX17725 | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| Placebo | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| BCX17725 | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| Placebo | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| BCX17725 | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| Placebo | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| BCX17725 | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| Placebo | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| BCX17725 | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| avoralstat | Other | Phase PHASE1 | Diabetic Macular Edema (DME) | TERMINATED | NCT07228559 |
| avoralstat | Other | Phase PHASE1 | Diabetic Macular Edema (DME) | TERMINATED | NCT07228559 |
| avoralstat | Other | Phase PHASE1 | Diabetic Macular Edema (DME) | TERMINATED | NCT07228559 |
| avoralstat | Other | Phase PHASE1 | Diabetic Macular Edema (DME) | TERMINATED | NCT07228559 |
| avoralstat | Other | Phase PHASE1 | Diabetic Macular Edema (DME) | TERMINATED | NCT07228559 |
| avoralstat | Other | Phase PHASE1 | Diabetic Macular Edema (DME) | TERMINATED | NCT07228559 |
| Ulodesine (BCX4208) 10 mg | Other | Phase PHASE2 | Gout | COMPLETED | NCT01407874 |
| Ulodesine (BCX4208) 5 mg | Other | Phase PHASE2 | Gout | COMPLETED | NCT01407874 |
| Placebo | Other | Phase PHASE2 | Gout | COMPLETED | NCT01407874 |
| Peramivir | Other | Phase PHASE2 | Influenza | COMPLETED | NCT02665351 |
| Placebo | Other | Phase PHASE1 | Filovirus Infections | COMPLETED | NCT02319772 |
| BCX4430 | Other | Phase PHASE1 | Filovirus Infections | COMPLETED | NCT02319772 |
| Cyclosporine + BCX7353 | Other | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT03136237 |
| rosuvastatin + BCX7353 | Other | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT03136237 |
| Rosuvastatin | Other | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT03136237 |
| BCX7353 + digoxin | Other | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT03136237 |
| Digoxin | Other | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT03136237 |
| BCX7353 | Other | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT03136237 |
| Berotralstat | Other | Preclinical | Hereditary Angioedema | APPROVED_FOR_MARKETING | NCT04428632 |
| placebo | Other | Phase PHASE1 | Marburg Virus Disease | COMPLETED | NCT03800173 |
| galidesivir | Other | Phase PHASE1 | Marburg Virus Disease | COMPLETED | NCT03800173 |
| BCX7353 | Other | Phase PHASE2 | Hereditary Angioedema | COMPLETED | NCT03472040 |
| BCX10013 | Other | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT06100900 |
| BCX4208 | Other | Phase PHASE2 | Gout | COMPLETED | NCT01129648 |
| Allopurinol | Other | Phase PHASE2 | Gout | COMPLETED | NCT01129648 |
| Placebo | Other | Phase PHASE2 | Gout | COMPLETED | NCT01129648 |
| BCX4208 | Other | Phase PHASE2 | Gout | COMPLETED | NCT00985127 |
| placebo | Other | Phase PHASE2 | Gout | COMPLETED | NCT00985127 |
| Placebo | Other | Phase PHASE2 | Gout | COMPLETED | NCT01265264 |
| ulodesine | Other | Phase PHASE2 | Gout | COMPLETED | NCT01265264 |
| BCX4161 | Other | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT02125162 |
| Placebo | Other | Phase PHASE2 | Hereditary Angioedema | COMPLETED | NCT01984788 |
| BCX4161 | Other | Phase PHASE2 | Hereditary Angioedema | COMPLETED | NCT01984788 |
| BCX4161 | Other | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT02218294 |
| Placebo Comparator | Other | Phase PHASE3 | Influenza | TERMINATED | NCT01224795 |
| Peramivir | Other | Phase PHASE3 | Influenza | TERMINATED | NCT01224795 |
| Placebo to match BCX7353 | Other | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT02448264 |
| BCX7353 | Other | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT02448264 |
| avoralstat | Other | Phase PHASE3 | Hereditary Angioedema | TERMINATED | NCT02670720 |
| BCX7353 and probes | Other | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT02819102 |
| BCX7353 | Other | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT03202784 |
| Placebo | Other | Phase PHASE2 | Hereditary Angioedema (HAE) | COMPLETED | NCT02870972 |
| BCX7353 | Other | Phase PHASE2 | Hereditary Angioedema (HAE) | COMPLETED | NCT02870972 |
| Peramivir | Other | Phase PHASE3 | Influenza | COMPLETED | NCT02635724 |
| Oseltamivir | Other | Phase PHASE3 | Influenza | COMPLETED | NCT02369159 |
| Peramivir | Other | Phase PHASE3 | Influenza | COMPLETED | NCT02369159 |
| Placebo | Other | Phase PHASE2 | Hereditary Angioedema (HAE) | COMPLETED | NCT03240133 |
| BCX7353 | Other | Phase PHASE2 | Hereditary Angioedema (HAE) | COMPLETED | NCT03240133 |
| Placebo | Other | Phase PHASE1 | COVID-19 | TERMINATED | NCT03891420 |
| Galidesivir | Other | Phase PHASE1 | COVID-19 | TERMINATED | NCT03891420 |
| Placebo | Other | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT04330534 |
| BCX9930 | Other | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT04330534 |
| Placebo oral capsule | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT03485911 |
| BCX7353 capsules | Other | Phase PHASE3 | Hereditary Angioedema | COMPLETED | NCT03485911 |
| BCX9930 | Other | Phase PHASE2 | Complement 3 Glomerulopathy | TERMINATED | NCT05162066 |
| Placebo oral capsule | Other | Phase PHASE3 | Hereditary Angioedema, HAE | COMPLETED | NCT03873116 |
| BCX7353 capsules | Other | Phase PHASE3 | Hereditary Angioedema, HAE | COMPLETED | NCT03873116 |
| BCX9930 monotherapy | Drug | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | TERMINATED | NCT05116787 |
| Placebo | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | TERMINATED | NCT05116787 |
| BCX9930 | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | TERMINATED | NCT05116774 |
| Ravulizumab | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | TERMINATED | NCT05116774 |
| Eculizumab | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | TERMINATED | NCT05116774 |
| Ravulizumab | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria | TERMINATED | NCT04702568 |
| Eculizumab | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria | TERMINATED | NCT04702568 |
| BCX9930 | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria | TERMINATED | NCT04702568 |
| BCX9930 | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria | TERMINATED | NCT05741346 |
| Placebo | Other | Phase PHASE2 | Hereditary Angioedema | COMPLETED | NCT02303626 |
| BCX4161 | Other | Phase PHASE2 | Hereditary Angioedema | COMPLETED | NCT02303626 |
| berotralstat | Other | Phase PHASE3 | Hereditary Angioedema | ENROLLING_BY_INVITATION | NCT04933721 |
| Berotralstat | Other | Phase PHASE3 | Hereditary Angioedema | ACTIVE_NOT_RECRUITING | NCT05453968 |
| Placebo | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| BCX17725 | Other | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| avoralstat | Other | Phase PHASE1 | Diabetic Macular Edema (DME) | ACTIVE_NOT_RECRUITING | NCT07228559 |
| BTA-C585 matching placebo | DRUG | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02668367 |
| BTA-C585 oral capsules | DRUG | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT02668367 |
| Vapendavir 132 mg capsules | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02101866 |
| Vapendavir 300 mg tablet | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02101866 |
| Vapendavir | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT02367313 |
| BCX17725 | DRUG | Phase PHASE1 | Netherton Syndrome | RECRUITING | NCT06539507 |
| BCX10013 | DRUG | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT06100900 |
| BCX9930 monotherapy | DRUG | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | TERMINATED | NCT05116787 |
| berotralstat | DRUG | Phase PHASE3 | Hereditary Angioedema | ENROLLING_BY_INVITATION | NCT04933721 |
| Ravulizumab | DRUG | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | TERMINATED | NCT05116774 |
| Eculizumab | DRUG | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | TERMINATED | NCT05116774 |
| Berotralstat | DRUG | Phase PHASE3 | Hereditary Angioedema | ACTIVE_NOT_RECRUITING | NCT05453968 |
| BCX9930 | DRUG | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria | TERMINATED | NCT05741346 |
| Galidesivir | DRUG | Phase PHASE1 | COVID-19 | TERMINATED | NCT03891420 |
| galidesivir | DRUG | Phase PHASE1 | Marburg Virus Disease | COMPLETED | NCT03800173 |
| Placebo oral capsule | DRUG | Phase PHASE3 | Hereditary Angioedema, HAE | COMPLETED | NCT03873116 |
| BCX7353 capsules | DRUG | Phase PHASE3 | Hereditary Angioedema, HAE | COMPLETED | NCT03873116 |
| Cyclosporine + BCX7353 | DRUG | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT03136237 |
| rosuvastatin + BCX7353 | DRUG | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT03136237 |
| Rosuvastatin | DRUG | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT03136237 |
| BCX7353 + digoxin | DRUG | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT03136237 |
| Digoxin | DRUG | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT03136237 |
| BCX7353 and probes | DRUG | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT02819102 |
| avoralstat | DRUG | Phase PHASE1 | Diabetic Macular Edema (DME) | ACTIVE_NOT_RECRUITING | NCT07228559 |
| Placebo to match BCX7353 | DRUG | Phase PHASE1 | Hereditary Angioedema | COMPLETED | NCT02448264 |
| BCX7353 | DRUG | Phase PHASE2 | Hereditary Angioedema | COMPLETED | NCT03472040 |
| BCX4430 | DRUG | Phase PHASE1 | Filovirus Infections | COMPLETED | NCT02319772 |
| BCX4161 | DRUG | Phase PHASE2 | Hereditary Angioedema | COMPLETED | NCT02303626 |
| Ulodesine (BCX4208) 10 mg | DRUG | Phase PHASE2 | Gout | COMPLETED | NCT01407874 |
| Ulodesine (BCX4208) 5 mg | DRUG | Phase PHASE2 | Gout | COMPLETED | NCT01407874 |
| ulodesine | DRUG | Phase PHASE2 | Gout | COMPLETED | NCT01265264 |
| Placebo Comparator | DRUG | Phase PHASE3 | Influenza | TERMINATED | NCT01224795 |
| Allopurinol | DRUG | Phase PHASE2 | Gout | COMPLETED | NCT01129648 |
| BCX4208 | DRUG | Phase PHASE2 | Gout | COMPLETED | NCT01129648 |
| placebo | DRUG | Phase PHASE1 | Marburg Virus Disease | COMPLETED | NCT03800173 |
| Placebo+SOC | DRUG | Phase PHASE3 | Cough | TERMINATED | NCT00958776 |
| Peramivir+SOC | DRUG | Phase PHASE3 | Cough | TERMINATED | NCT00958776 |
| forodesine HCl | DRUG | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | COMPLETED | NCT00640523 |
| Oseltamivir | DRUG | Phase PHASE3 | Influenza | COMPLETED | NCT02369159 |
| Peramivir 400 mg | DRUG | Phase PHASE2 | Influenza | COMPLETED | NCT00453999 |
| Peramivir 200 mg | DRUG | Phase PHASE2 | Influenza | COMPLETED | NCT00453999 |
| forodesine hydrochloride (BCX-1777) | DRUG | Phase PHASE1 | B-cell Acute Lymphoblastic Leukemia | COMPLETED | NCT00289562 |
| Peramivir | DRUG | Phase PHASE2 | Influenza | COMPLETED | NCT02665351 |
| Forodesine 200 mg | DRUG | Phase PHASE2 | Cutaneous T-cell Lymphoma (CTCL), | COMPLETED | NCT00501735 |
| Peramivir 300mg | DRUG | Phase PHASE3 | Influenza | WITHDRAWN | NCT00486980 |
| Peramivir 150mg | DRUG | Phase PHASE3 | Influenza | WITHDRAWN | NCT00486980 |
| Placebo | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT02367313 |
| Peramivir 300 mg | DRUG | Phase PHASE2 | Influenza | COMPLETED | NCT00419263 |
| Peramivir 150 mg | DRUG | Phase PHASE2 | Influenza | COMPLETED | NCT00419263 |
| Forodesine Hydrochloride Capsules (100 mg) | DRUG | Phase PHASE2 | Leukemia | TERMINATED | NCT00419081 |
| Forodesine Hydrochloride Sterile Solution, 5 mg/mL | DRUG | Phase PHASE2 | Leukemia | TERMINATED | NCT00419081 |
| forodesine hydrochloride | DRUG | Phase PHASE1 | Lymphoma | COMPLETED | NCT00098332 |
| BCX-1777 | DRUG | Phase PHASE1 | Leukemia, Lymphocytic | COMPLETED | NCT00035022 |
| Peldesine | DRUG | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002237 |
Total products: 163